<DOC>
	<DOCNO>NCT00302510</DOCNO>
	<brief_summary>The purpose study assess efficacy safety immunoadsorption treatment lipoprotein glomerulopathy .</brief_summary>
	<brief_title>Therapeutic Effect Immunoadsorption Patients With Lipoprotein Glomerulopathy</brief_title>
	<detailed_description>Lipoprotein glomerulopathy characterize nephritic syndrome glomerular protein thrombus lipid abnormality , particularly elevate level plasma apoprotein E ( apoE ) .There efficiency way treat lipoprotein glomerulopathy . We firstly successfully treat 2 patient protein A immunoadsorption remarkable decrease urine protein reduction lipoprotein thrombus repeat renal biopsy .</detailed_description>
	<criteria>1 . A new diagnosis lipoprotein glomerulopathy prove histology serology 2 . Age 15~60 year , sex free 1 . Serum creatinine &gt; 500 umol/l 2 . Severe viral infection ( HBV , HCV , CMV ) within 3 month first randomization know HIV infection 3 . Congenital acquire immunodeficiency 4 . Patients severe infection central nervous system symptoms 5 . Immediately lifethreatening organ manifestation ( e.g . lung haemorrhage massive gastrointestinal bleeding , heart failure due pericarditis myocarditis , liver dysfunction measure least 2 separate occasion )</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2008</verification_date>
	<keyword>lipoprotein glomerulopathy</keyword>
	<keyword>treatment</keyword>
	<keyword>immunoadsorption</keyword>
	<keyword>apolipoprotein E</keyword>
</DOC>